Stifel Financial Corp Biocryst Pharmaceuticals Inc Transaction History

Stifel Financial Corp

$85.8 Billion
Q1 2024

A detailed history of Stifel Financial Corp transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Stifel Financial Corp holds 1,843,936 shares of BCRX stock, worth $11.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,843,936

Previous 1,844,055 0.01%

Holding current value

$11.8 Million

Previous $11 Million 15.19%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.89 - $7.65 $581 - $910	-119 Reduced 0.01%	1,843,936 $9.37 Million
Q4 2023 Feb 12, 2024	BUY	$4.98 - $6.77 $179 - $243	36 Added 0.0%	1,844,055 $11 Million
Q3 2023 Nov 13, 2023	SELL	$6.71 - $7.92 $3,589 - $4,237	-535 Reduced 0.03%	1,844,019 $13.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $3,340 - $4,228	480 Added 0.03%	1,844,554 $13 Million
Q4 2022 Feb 13, 2023	SELL	$10.5 - $14.2 $22,050 - $29,820	-2,100 Reduced 0.11%	1,844,074 $21.2 Million

Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $41,541 - $57,018	-3,850 Reduced 0.21%	1,846,174 $23.3 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $2,509 - $5,685	-318 Reduced 0.02%	1,850,024 $19.6 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $9,456 - $16,163	818 Added 0.04%	1,850,342 $30.1 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $9,279 - $12,831	-830 Reduced 0.04%	1,849,524 $25.6 Million
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $1.41 Million - $2.61 Million	-191,745 Reduced 9.39%	1,850,354 $18.8 Million
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $93,423 - $275,843	-49,170 Reduced 2.35%	2,042,099 $9.73 Million
Q1 2020 May 14, 2020	BUY	$1.6 - $4.11 $3.35 Million - $8.6 Million	2,091,269 New	2,091,269 $4.18 Million

Others Institutions Holding BCRX

# of Institutions

256

Shares Held

182M

Call Options Held

839K

Put Options Held

816K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.19B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Biocryst Pharmaceuticals Inc Transaction History